Drug Search Results
More Filters [+]

Alvocidib

Alternative Names: alvocidib, flavopiridol, flavopiridol (alvocidib)
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)

Mechanisms of Action: CDK9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Alvocidib

Countries in Clinic: Germany, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

M16-186

P1

Completed

Acute Myeloid Leukemia

2021-01-25

28%

Recent News Events